z-logo
Premium
Synthesis and Evaluation of New 4‐Chloro‐2‐(3‐chloro‐4‐fluorophenyl)‐5‐(aliphatic/cyclic saturated amino)pyridazin‐3(2 H )‐one Derivatives as Anticancer, Antiangiogenic, and Antioxidant Agents
Author(s) -
Kamble Vinod T.,
Sawant Ajay S.,
Sawant Sanjay S.,
Pisal Parshuram M.,
Gacche Rajesh N.,
Kamble Sonali S.,
Kamble Vilas A.
Publication year - 2015
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201400442
Subject(s) - chemistry , antioxidant , dpph , stereochemistry , ascorbic acid , bromide , hydrazine (antidepressant) , biological activity , biochemistry , in vitro , organic chemistry , food science
Pyridazinones are widely recognized as versatile scaffolds with a wide spectrum of biological activities. In the present work, a series of new 4‐chloro‐2‐(3‐chloro‐4‐fluorophenyl)‐5‐(aliphatic/cyclic saturated amino)pyridazin‐3(2 H )‐one derivatives 4a – i were synthesized and characterized by spectral techniques. The inhibitory effects of the synthesized compounds 4a – i on the viability of three human cancer cell lines, HEP3BPN 11 (liver), MDA 453 (breast), and HL 60 (leukemia), were assessed using the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) reduction assay. Among the compounds 4a – i screened, 4g and 4i exhibited inhibitory activity very close to the standard methotrexate; therefore, these lead compounds were further tested for their potential to inhibit the proangiogenic cytokines involved in tumor progression. Compound 4g was found to be a potent antiangiogenic agent against TNFα, VEGF, FGFb, and TGFβ, whereas 4i showed potent antiangiogenic activity against TNFα, VEGF, FGFb, and leptin. All the compounds 4a – i were screened for their antioxidant activities using 2,2‐diphenyl‐1‐picryl hydrazine (DPPH), OH, and superoxide anion radicals. Compound 4f showed better OH radical scavenging activity than the standard ascorbic acid.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here